Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis

Histology and Histopathology

Volumn 24, Issue 2, 2009, Pages 175-185

  Pizzi, Sara ^a   Porzionato, Andrea ^a   Pasquali, Claudio ^a   Guidolin, Diego ^a   Sperti, Cosino ^a   Fogar, Paola ^a   Macchi, Veronica ^a   De Caro, Raffaele ^a   Pedrazzoli, Sergio ^a   Parenti, Anna ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Glut 1; Immunohistochemistry; Pancreatic adenocarcinoma; PanIN; Survival

Indexed keywords

GLUCOSE TRANSPORTER 1; SLC2A1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GRADING; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DYSPLASIA; FEMALE; GLUCOSE TRANSPORT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PROGNOSIS; PROTEIN EXPRESSION; ADENOCARCINOMA; BIOSYNTHESIS; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PHYSIOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 59149092066     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Adsay N.V., Longnecker D.S. and Klimstra D.S. (2000). Pancreatic tumors with cystic dilatation of the ducts: intraductal papillary mucinous neoplasms and intraductal oncocytic papillary neoplasms. Semin. Diagn. Pathol. 17, 16-30.
2. Airley R.E. and Mobasheri A. (2007). Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53, 233-256.
3. Biankin A.V., Kench J.G., Dijkman F.P., Biankin S.A. and Henshall S.M. (2003). Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. Pathology 35, 14-24.
4. Bos R., van Der Hoeven J.J., van Der Wall E., van Der Groep P., van Diest P.J., Comans E.F., Joshi U., Semenza G.L., Hoekstra O.S., Lammertsma A.A. and Molthoff C.F. (2002). Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J. Clin. Oncol. 20, 379-387.
5. Cantuaria G., Fagotti A., Ferrandina G., Magalhaes A., Nadji M., Angioli R., Penalver M., Mancuso S. and Scambia G. (2001). GLUT-1 expression in ovarian carcinoma. Association with survival and response to chemotherapy. Cancer 92, 1144-1150.
6. Chan J.Y., Kong S.K., Choy Y.M., Lee C.Y. and Fung K.P. (1999). Inhibition of glucose transporter gene expression by antisense nucleic acids in HL-60 leukemia cells. Life Sci. 65, 63-70.
7. Chang S., Lee S., Lee C., Kim J.I. and Kim Y. (2000). Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology 55, 448-452.
8. Cooper R., Sarioglu S., Sokmen S., Fuzun M., Kupelioglu A., Valentine H., Gorken I.B., Airley R. and West C. (2003). Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br. J. Cancer 89, 870-876.
9. Cornford E.M., Hyman S. and Swartz B.E. (1994). The human brain GLUT 1 glucose transporter: ultrastructural localization of the blood-brain barrier endothelia. J. Cereb. Blood Flow Metab. 14, 106-112.
10. Ebert B.L., Firth J.D. and Ratcliffe P.J. (1995). Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J. Biol. Chem. 270, 29083-29089.
11. Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G. and Morrow M. (2002). American Joint Committee of Cancer Cancer Staging Manual. 6th ed. Springer-Verlag. New York, NY.
12. Haber R.S., Rathan A., Weiser K.R., Pritsker A., Itzkowitz S.H., Bodian C., Slater G., Weiss A. and Burstein D.E. (1998). GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83, 34-40.
13. Halloran C.M., Ghaneh P., Neoptolemos J.P. and Costello E. (2000). Gene therapy for pancreatic cancer - current and prospective strategies. Surg. Oncol. 9, 181-191.
14. Higashi T., Tamaki N., Honda T., Torizuka T., Kimura T., Inokuma T., Ohshio G., Hosotani R., Imamura M. and Konishi J. (1997). Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J. Nucl. Med. 38, 1337-1344.
15. Hruban R.H., Wilentz R.E. and Kern S.E. (2000). Genetic progression in the pancreatic ducts. Am. J. Pathol. 156, 1821-1825.
16. Ito H., Duxbury M., Zinner M.J., Ashley S.W. and Whang E.E. (2004). Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery 136, 548-556.
17. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C. and Thun M.J. (2006). Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130.
18. Kalir T., Wang B.Y., Goldfischer M., Haber R.S., Reder I., Demopoulos R., Cohen C.J. and Burstein D.E. (2002). Immunohistochemical staining of GLUT 1 in benign, borderline, and malignant ovarian epithelia. Cancer 94, 1078-1082.
19. Kim Y.W., Park Y-K., Yoon T.Y. and Lee S.M. (2002). Expression of the GLUT 1 glucose transporter in gallbladder carcinomas. Hepatogastroenterology 49, 907-911.
20. Kloppel G., Hruban R.H., Longnecker D.S., Adler G., Kern S.E. and Partanen T.J. (2000). Ductal adenocarcinoma of the pancreas. In: Pathology and genetics. Tumors of the digestive system. WHO Classification Of Tumors. Hamilton S.R., Aaltonen L.A. (eds). IARC Press. Lyon. pp 221-230.
21. Kurokawa T., Yoshida Y., Kawahara K., Tsuchida T., Okazawa H., Fujibayashi Y., Yonekura Y. and Kotsuji F. (2004). Expression of GLUT 1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int. J. Cancer 109, 926-932.
22. Lim J.E., Chien M.W. and Earle C.C. (2003). Prognostic factors following curative resection for pancreatic adenocarcinoma. A population-based, linked database analysis of 396 patients. Ann. Surg. 237, 74-85.
23. Lyshchik A., Higashi T., Hara T., Nakamoto Y., Fujimoto K., Doi R., Imamura M., Saga T. and Togashi K. (2007). Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest. 25, 154-162.
24. Mendez L.E., Manci N., Cantuaria G., Gomez-Marin O., Penalver M., Braunschweiger P. and Nadji M. (2002). Expression of glucose transporter-1 in cervical cancer and its precursors. Gynecol. Oncol. 86, 138-143.
25. Minami K.I., Saito Y., Imamura H. and Okamura A. (2002). Prognostic significance of p53, Ki-67, VEGF and GLUT-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 38, 51-57.
26. Mineta H., Miura K., Takebayashi S., Misawa K., Araki K., Misawa Y. and Ueda Y. (2002). Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. Anticancer Res. 22, 3489-3494.
27. Nakata B., Chung Y.S., Nishimura S., Nishihara T., Sakurai Y., Sawada T., Okamura T., Kawabe J., Ochi H. and Sowa M. (1997). 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79, 695-699.
28. Noguchi Y., Saito A., Miyagi Y., Yamanaka S., Marat D., Doi C., Yoshikawa T., Tsuburaya A., Ito T. and Satoh S. (2000). Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett. 154, 175-182.
29. Pedrazzoli S., Pasquali C., Sperti C. and Chierichetti F. (2005). 18-fluorodeoxyglucose positron emission tomography and pancreatic cancer. Dig. Surg. 22, 467-469.
30. Pessin J.E. and Bell G.I. (1992). Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu. Rev. Physiol. 54, 911-930.
31. Reisser C., Eichhorn K., Herold-Mende C., Born A.I. and Bannasch P. (1999). Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int. J. Cancer 80, 194-198.
32. Reske S.N., Grillenberger K.G., Glatting G., Port M., Hildebrandt M., Gansauge F. and Beger H.G. (1997). Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J. Nucl. Med. 38, 1344-1348.
33. Rickaert F., Cremer M., Devière J., Tavares L., Lambilliotte J.P., Schröder S., Wurbs D. and Klöppel G. (1991). Intraductal mucinhypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients. Gastroenterology 101, 512-519.
34. Rudlowski C., Moser M., Becker A.J., Rath W., Buttner R., Schroder W. and Schurmann A. (2004). GLUT 1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology 66, 404-410.
35. Sperti C., Pasquali C., Catalini S., Cappellazzo F., Bonadimani B., Behboo R. and Pedrazzoli S. (1993). CA 19-9 as a prognostic index after resection for pancreatic cancer. J. Surg. Oncol. 52, 137-141.
36. Sperti C., Pasquali C., Chierichetti F., Ferronato A., Decet G. and Pedrazzoli S. (2003). 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J. Gastrointest. Surg. 7, 953-960.
37. Sun H.C., Qiu Z.J., Liu J., Sun J., Jiang T., Huang K.J., Yao M. and Huang C. (2007). Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int. J. Oncol. 30, 1359-1367.
38. Tateishi U., Yamaguchi U., Seki K., Terauchi T., Arai Y. and Hasegawa T. (2006). Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [(18)F]fluorodeoxyglucose positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 33, 683-691.
39. Vogel I., Kalthoff H., Henne-Bruns D. and Kremer B. (2002). Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma. Pancreatology 2, 79-88.
40. Wang B.Y., Kalir T., Sabo E., Sherman D.E., Cohen C. and Burstein D.E. (2000). Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer 88, 2774-2781.
41. Wittekind C., Compton C., Greene F.L. and Sobin L.H. (2002). TNM residual tumor classification revisited. Cancer 94, 2511-2519.
42. Younes M., Lechago L.V. and Lechago J. (1996). Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin. Cancer Res. 2, 1151-1154.